Search Result

Results for "

(±)-Naproxen

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (5) Biochemical Assay Reagents (1) COX (16) Cytochrome P450 (1) Drug Intermediate (1) Drug Metabolite (2) Endogenous Metabolite (1) FLT3 (1) Isotope-Labeled Compounds (4) Ligands for Target Protein for PROTAC (1) PROTACs (1) Ras (1) Reference Standards (6) Trk Receptor (2)
By Research Areas:	Cancer (12) Inflammation/Immunology (16) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15029

(±)-Naproxen (Rac)-Naproxen; 2-(6-Methoxynaphthalen-2-yl)propanoic acid	COX	Inflammation/Immunology Cancer
(±)-Naproxen ((Rac)-Naproxen) is a racemate of Naproxen (HY-15030). Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively.

HY-15029S

*(±)-Naproxen-d3* (Rac)-Naproxen-d₃	COX Isotope-Labeled Compounds	Inflammation/Immunology
(±)-Naproxen-d₃ is the deuterium labeled (±)-Naproxen. (±)-Naproxen is a non-steroidal anti-inflammatory drug (NSAID) .

HY-15031

l-Naproxen (R)-Naproxen	Ras	Cancer
l-Naproxen ((R)-Naproxen) is an enantiomer of (S)-Naproxen. l-Naproxen can inhibit Cdc42 and Rac1 (EC₅₀=96 μM and 212 μM, respectively), and show anti-tumor activity. l-Naproxen is a nonsteroidal antiinflammatory agent (NSAID) .

HY-15030R

Naproxen (Standard) (S)-Naproxen (Standard)	Reference Standards COX Autophagy	Inflammation/Immunology Cancer
Naproxen (Standard) is the analytical standard of Naproxen. This product is intended for research and analytical applications. Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

HY-132405S

*Desmethyl Naproxen-d3*	COX Autophagy	Others
Desmethyl Naproxen-d₃ is deuterium labeled Desmethyl Naproxen. Desmethyl Naproxen is the metabolite of anti-inflammatory agent Naproxen .

HY-15029R

*(±)-Naproxen* (Standard)** (Rac)-Naproxen (Standard); 2-(6-Methoxynaphthalen-2-yl)propanoic acid (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
(±)-Naproxen (Standard) is the analytical standard of (±)-Naproxen. This product is intended for research and analytical applications. (±)-Naproxen ((Rac)-Naproxen) is a racemate of Naproxen (HY-15030). Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively.

HY-15029S2

*(±)-Naproxen-13C,d3*	COX	Cancer
(±)-Naproxen- ¹³C,d₃ is the deuterium and ¹³C labeled (±)-Naproxen . (±)-Naproxen ((Rac)-Naproxen) is a racemate of Naproxen (HY-15030). Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively.

HY-15029S1

*(±)-Naproxen-d3-1* (Rac)-Naproxen-d₃-1 (α-methyl-d₃)	COX Isotope-Labeled Compounds	Others
(±)-Naproxen-d₃-1 is the deuterium labeled (±)-Naproxen .

HY-W777599

*(±)-Naproxen-13C,d3-1* (Rac)-Naproxen-¹³C,d₃-1	Isotope-Labeled Compounds	Others
(±)-Naproxen- ¹³C,d₃-1 ((Rac)-Naproxen- ¹³C,d₃-1) is ¹³C and deuterium labeled (±)-Naproxen .

HY-W121901

Naproxen glucuronide (S)-Naproxen-β-D-glucuronide	COX	Inflammation/Immunology
Naproxen glucuronide ((S)-Naproxen-β-D-glucuronide) is a non-selective COX inhibitor. Naproxen glucuronide, a metabolite of naproxen, is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid class (the same as ibuprofen) that relieves pain, fever, swelling, and stiffness .

HY-W339645

Naproxen ethyl ester (S)-Naproxen ethyl ester	COX	Inflammation/Immunology
Naproxen ethyl ester ((S)-Naproxen ethyl ester) is a nonsteroidal anti-inflammatory drug with activity in relieving pain, fever, swelling and stiffness. Naproxen ethyl ester exerts its effects by inhibiting non-selective cyclooxygenase (COX). The R-(-)-isomer of Naproxen ethyl ester shows stronger immunogenicity, and the Michaelis-Menten parameter of its catalytic reaction is K(M)=6.67 mM, and the catalytic efficiency is 5.8 x 10^4 times higher than that of the non-catalytic reaction .

HY-15030AR

Naproxen sodium (Standard)	Reference Standards Autophagy COX	Inflammation/Immunology Cancer
Naproxen (sodium) (Standard) is the analytical standard of Naproxen (sodium). This product is intended for research and analytical applications. Naproxen sodium is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

HY-15030S1

Naproxen-d3 (S)-Naproxen-d₃	Isotope-Labeled Compounds	Others
Naproxen-d₃ is the deuterium labeled Naproxen. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified .

HY-15030

*Naproxen* 4 Publications Verification (S)-Naproxen	COX Autophagy	Inflammation/Immunology Cancer
Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

HY-W699926

*(R)-Naproxen* acyl-β-D-glucuronide** (R)-Naproxen-β-D-glucuronide	Biochemical Assay Reagents
(R)-Naproxen acyl-β-D-glucuronide ((R)-Naproxen-β-D-glucuronide) is a compound metabolite with anti-inflammatory activity. (R)-Naproxen acyl-β-D-glucuronide can serve as a sensitive fluorescent substrate for proglutamyl peptidase 1, which produces a blue reaction after cleavage.

HY-15030A

Naproxen sodium 4 Publications Verification	Autophagy COX	Inflammation/Immunology Cancer
Naproxen sodium is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

HY-131495

(S)-6-O-Desmethylnaproxen (S)-6-Desmethyl Naproxen	COX	Inflammation/Immunology
(S)-6-O-Desmethylnaproxen ((S)-6-Desmethyl Naproxen) is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (+)-naproxen ((S)-naproxen). (S)-6-O-Desmethylnaproxen is formed from (S)-naproxen by the cytochrome P450 (CYP) isoforms CYP1A2 and CYP2C9.

HY-169374

Naproxen Gilteritinib	Ligands for Target Protein for PROTAC	Cancer
Naproxen Gilteritinib is the active reference substance of Gilteritinib (HY-12432). Gilteritinib is the target protein ligand of PROTAC degrader LWY713 (HY-157213) .

HY-19675

Naproxen etemesil LT-NS 001; MX 1094	COX	Inflammation/Immunology
Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

HY-131495R

(S)-6-O-Desmethylnaproxen (Standard) (S)-6-Desmethyl Naproxen (Standard)	Cytochrome P450 Reference Standards	Inflammation/Immunology
(S)-6-O-Desmethylnaproxen (Standard) is the analytical standard of (S)-6-O-Desmethylnaproxen. This product is intended for research and analytical applications. (S)-6-O-Desmethylnaproxen ((S)-6-Desmethyl Naproxen) is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (+)-naproxen ((S)-naproxen). (S)-6-O-Desmethylnaproxen is formed from (S)-naproxen by the cytochrome P450 (CYP) isoforms CYP1A2 and CYP2C9.

HY-B2121

6-Methoxy-2-naphthoic acid 6-MNA; Naproxen impurity O	Drug Metabolite COX	Neurological Disease Inflammation/Immunology
6-Methoxy-2-naphthoic acid (6-MNA) is the active metabolite of Nabumetone (HY-B0559). 6-Methoxy-2-naphthoic acid is also an inhibitor of COX-1 and COX-2. 6-Methoxy-2-naphthoic acid can inhibit the synthesis of gastric mucosal prostaglandin E₂. 6-Methoxy-2-naphthoic acid can be used in the research of inflammation and pain-related diseases. In addition, 6-Methoxy-2-naphthoic acid is an impurity in Naproxen (HY-15030) and can also be used in the synthesis of other active compounds .

HY-B2121R

6-Methoxy-2-naphthoic acid (Standard) 6-MNA (Standard); Naproxen impurity O (Standard)	Reference Standards Drug Metabolite COX	Neurological Disease Inflammation/Immunology
6-Methoxy-2-naphthoic acid (Standard) (6-MNA (Standard)) is the analytical standard of 6-Methoxy-2-naphthoic acid (HY-B2121). This product is intended for research and analytical applications. 6-Methoxy-2-naphthoic acid (6-MNA) is the active metabolite of Nabumetone (HY-B0559). 6-Methoxy-2-naphthoic acid is also an inhibitor of COX-1 and COX-2. 6-Methoxy-2-naphthoic acid can inhibit the synthesis of gastric mucosal prostaglandin E₂. 6-Methoxy-2-naphthoic acid can be used in the research of inflammation and pain-related diseases. In addition, 6-Methoxy-2-naphthoic acid is an impurity in Naproxen (HY-15030) and can also be used in the synthesis of other active compounds.

HY-W702781

1,3-Distearin 1,3-Distearoyl glycerol; Glyceryl 1,3-distearate; DG(18:0/0:0/18:0)	Drug Intermediate	Inflammation/Immunology
1,3-Distearin (1,3-Distearoyl glycerol) is an intermediate for synthesizing non-steroidal anti-inflammatory agents, and can be used in the synthesis of Ibuprofen (HY-78131), Naproxen (HY-15030), Diclofenac (HY-15036), and other non-steroidal anti-inflammatory agents .

HY-Y0038

2-Bromo-6-methoxynaphthalene	Trk Receptor	Cancer
2-Bromo-6-methoxynaphthalene is an active intermediate in the production of anti-inflammatory agents like Naproxen and Nabumetone by Heck reaction. 2-Bromo-6-methoxynaphthalene has potential anti-inflammatory properties and Tyrosine-protein inhibitor properties. 2-Bromo-6-methoxynaphthalene can be used for the research of cancer .

HY-118756

Anirolac RS37326	Endogenous Metabolite	Inflammation/Immunology
Anirolac (RS37326) is a nonsteroidal anti-inflammatory agent with analgesic activity. Anirolac showed analgesic efficacy comparable to that of naproxen in suppressing moderate or severe postpartum uterine pain. Anirolac induced significantly higher analgesia scores than placebo within 6 hours, especially at the 100 mg dose. Anirolac effectively relieved pain and showed a stronger analgesic effect than placebo in every assessment .

HY-Y0038R

2-Bromo-6-methoxynaphthalene (Standard)	Reference Standards Trk Receptor	Cancer
2-Bromo-6-methoxynaphthalene (Standard) is the analytical standard of 2-Bromo-6-methoxynaphthalene. This product is intended for research and analytical applications. 2-Bromo-6-methoxynaphthalene is an active intermediate in the production of anti-inflammatory agents like Naproxen and Nabumetone by Heck reaction. 2-Bromo-6-methoxynaphthalene has potential anti-inflammatory properties and Tyrosine-protein inhibitor properties. 2-Bromo-6-methoxynaphthalene can be used for the research of cancer .

HY-157213

LWY713	Apoptosis PROTACs FLT3	Cancer
LWY713 is a PROTAC-class FLT3 degrader (DC₅₀=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).

Cat. No.	Product Name

HY-L130

Non-steroidal Anti-Inflammatory Compound Library	615 compounds
Non-steroidal anti-inflammatory drugs (NSAIDs) are members of a therapeutic drug class with potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. The most prominent NSAIDs are aspirin, ibuprofen, and naproxen. The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX), based on which NSAIDs can be classified into two types: non-selective and COX-2 selective. Most NSAIDs are non-selective and inhibit both COX-1 and COX-2 activity. MCE offers a unique collection of 615 non-steroidal compounds with identified anti-inflammatory activity. MCE non-steroidal anti-inflammatory library is a useful tool for the study of anti-inflammatory drugs and pharmacology.

Non-steroidal Anti-Inflammatory Compound Library

615 compounds

Non-steroidal anti-inflammatory drugs (NSAIDs) are members of a therapeutic drug class with potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. The most prominent NSAIDs are aspirin, ibuprofen, and naproxen.

The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX), based on which NSAIDs can be classified into two types: non-selective and COX-2 selective. Most NSAIDs are non-selective and inhibit both COX-1 and COX-2 activity.

MCE offers a unique collection of 615 non-steroidal compounds with identified anti-inflammatory activity. MCE non-steroidal anti-inflammatory library is a useful tool for the study of anti-inflammatory drugs and pharmacology.

Cat. No.	Product Name	Type